Recombinant Glial Fibrillary Acidic Protein (GFAP) | MyBioSource MBS2009299 product information

product summary

request information :

company name :

MyBioSource

product type :

protein

product name :

Recombinant Glial Fibrillary Acidic Protein (GFAP)

catalog :

MBS2009299

quantity :

0.01 mg

price :

235 USD

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS2009299

products type :

Recombinant Protein

products full name :

Recombinant Glial Fibrillary Acidic Protein (GFAP)

products short name :

Glial Fibrillary Acidic Protein (GFAP)

other names :

glial fibrillary acidic protein isoform 2; Glial fibrillary acidic protein; glial fibrillary acidic protein; glial fibrillary acidic protein; N/A

products gene name :

GFAP

other gene names :

GFAP; GFAP; GFAP

uniprot entry name :

GFAP_HUMAN

host :

E Coli

sequence length :

431

sequence :

The target protein is fused with two N-terminal Tags, His-tag and S-tag, its sequence is listed below. MHHHHHHSSG LVPRGSGMKE TAAAKFERQH MDSPDLGTDD DDKAMADIGS EF-EEWYRSKF ADLTDAAARN AELLRQAKHE ANDYRRQLQS LTCDLESLRG TNESLERQMR EQEERHVREA ASYQEALARL EEEGQSLKDE MARHLQEYQD LLNVKLALDI EIATYRKLLE GEE

purity :

> 95%

form :

Supplied as lyophilized form in PBS,pH7.4, containing 5% sucrose, 0.01% sarcosyl.

storage stability :

Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

tested application :

SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP)

other info1 :

Organism: Homo sapiens (Human). Expression System: Prokaryotic expression. Residues: Glu254~Glu374 (Accession # P14136) with two N-terminal Tags, His-tag and S-tag

other info2 :

Endotoxin Level: Reconstitute in sterile PBS, pH7.2-pH7.4.

products description :

About the Marker: Effective Size Range: 10kDa to 70kDa. Protein bands: 10kDa, 14kDa, 18kDa, 22kDa, 26kDa, 33kDa, 44kDa and70kDa. Double intensity bands: The 26kDa, 18kDa, 10kDa bands are at doubleintensity to make location and size approximation of proteins of interestquick and easy. Ready-to-use: No need to heat, dilute or add reducing agents before use.

ncbi gi num :

196115290

ncbi acc num :

NP_001124491.1

ncbi gb acc num :

NM_001131019.2

uniprot acc num :

P14136

ncbi mol weight :

20.0kDa

ncbi pathways :

Neural Crest Differentiation Pathway 672460!!Nuclear Signaling By ERBB4 Pathway 530744!!Signal Transduction Pathway 477114!!Signaling By ERBB4 Pathway 530741!!Spinal Cord Injury Pathway 739007

ncbi summary :

This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]

uniprot summary :

Function: GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. Subunit structure: Interacts with SYNM . By similarity. Isoform 3 interacts with PSEN1 (via N-terminus). Ref.16. Subcellular location: Cytoplasm. Note: Associated with intermediate filaments. Ref.16. Tissue specificity: Expressed in cells lacking fibronectin. Ref.3. Post-translational modification: Phosphorylated by PKN1. Ref.18 Ref.19 Ref.20. Involvement in disease: Alexander disease (ALEXD) [MIM:203450]: A rare disorder of the central nervous system. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death within the first decade. Infants with Alexander disease develop a leukodystrophy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. Histologically, Alexander disease is characterized by Rosenthal fibers, homogeneous eosinophilic inclusions in astrocytes.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.22 Ref.23 Ref.24 Ref.25 Ref.26 Ref.27. Sequence similarities: Belongs to the intermediate filament family.

size :

0.01 mg

price :

235 USD

more info or order :

MyBioSource product webpage